Payment overview · 2025
General Payments
$57.53
3 reported records · 2 companies
Healthcare provider profile · identity verified
Holly C Rigdon, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKSVILLE, MS · NPI 1821243924
Verified facts
What the public records show
CMS Open Payments records show Holly C Rigdon, NP received $57.53 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 62.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.68 | 62.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.85 | 38.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $57.53 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 750 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 96 |
| Omeprazole | Omeprazole | 300 | 54 |
| Gabapentin | Gabapentin | 295 | 59 |
| Lisinopril | Lisinopril | 291 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 44 |
| Potassium Chloride | Potassium Chloride | 236 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 30 |
| Metformin Hcl | Metformin Hcl | 231 | 42 |
| Meloxicam | Meloxicam | 221 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 35 |
| Losartan Potassium | Losartan Potassium | 196 | 47 |
| Metformin Hcl Er | Metformin Hcl | 184 | 34 |
| Montelukast Sodium | Montelukast Sodium | 177 | 36 |
| Carvedilol | Carvedilol | 169 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 35 |
| Furosemide | Furosemide | 164 | 33 |
| Famotidine | Famotidine | 152 | 25 |
| Farxiga | Dapagliflozin Propanediol | 147 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 26 |
| Azithromycin | Azithromycin | 87 | 73 |
| Buspirone Hcl | Buspirone Hcl | 86 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 14 |
| Allopurinol | Allopurinol | 84 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 12 |
| Glipizide | Glipizide | 78 | suppressed |
| Cefdinir | Cefdinir | 77 | 72 |
| Ezetimibe | Ezetimibe | 76 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 23 |
| Jardiance | Empagliflozin | 74 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 17 |
| Amoxicillin | Amoxicillin | 70 | 62 |
| Ozempic | Semaglutide | 65 | 13 |
| Sertraline Hcl | Sertraline Hcl | 63 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | suppressed |
| Mounjaro | Tirzepatide | 60 | 11 |
| Eliquis | Apixaban | 58 | 11 |
| Tramadol Hcl | Tramadol Hcl | 56 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Simvastatin | Simvastatin | 49 | 14 |
| Spironolactone | Spironolactone | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 35 |
| Fluconazole | Fluconazole | 45 | 28 |
| Clonidine Hcl | Clonidine Hcl | 44 | 11 |
| Trazodone Hcl | Trazodone Hcl | 43 | 14 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 37 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 14 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57.53 · 3 records | PFIZER INC. | ELIQUIS, MOUNJARO, NURTEC ODT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error